$19.37
18.76% day before yesterday
Nasdaq, Nov 01, 09:00 pm CET
ISIN
US0008991046
Symbol
ADMA
Sector
Industry

ADMA Biologics, Inc. Target price 2024 - Analyst rating & recommendation

ADMA Biologics, Inc. Classifications & Recommendation:

Buy
100%

ADMA Biologics, Inc. Price Target

Target Price $19.00
Price $19.37
Deviation
Number of Estimates 4
4 Analysts have issued a price target ADMA Biologics, Inc. 2025 . The average ADMA Biologics, Inc. target price is $19.00. This is lower than the current stock price. The highest price target is , the lowest is .
A rating was issued by 5 analysts: 5 Analysts recommend ADMA Biologics, Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the ADMA Biologics, Inc. stock has an average upside potential 2025 of . Most analysts recommend the ADMA Biologics, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 258.22 405.50
67.59% 57.04%
EBITDA Margin 11.60% 39.40%
155.07% 239.58%
Net Margin -11.73% 27.58%
76.49% 335.09%

4 Analysts have issued a sales forecast ADMA Biologics, Inc. 2024 . The average ADMA Biologics, Inc. sales estimate is

$406m
Unlock
. This is
22.79% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$410m 24.15%
Unlock
, the lowest is
$402m 21.70%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $258m 67.59%
2024
$406m 57.04%
Unlock
2025
$458m 13.00%
Unlock
2026
$511m 11.48%
Unlock
2027
$576m 12.76%
Unlock
2028
$689m 19.69%
Unlock

3 Analysts have issued an ADMA Biologics, Inc. EBITDA forecast 2024. The average ADMA Biologics, Inc. EBITDA estimate is

$160m
Unlock
. This is
73.12% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$164m 78.01%
Unlock
, the lowest is
$155m 67.71%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $30.0m 192.30%
2024
$160m 433.33%
Unlock
2025
$202m 26.55%
Unlock
2026
$243m 20.00%
Unlock
2027
$283m 16.81%
Unlock
2028
$360m 26.97%
Unlock

EBITDA Margin

2023 11.60% 155.07%
2024
39.40% 239.58%
Unlock
2025
44.13% 12.01%
Unlock
2026
47.50% 7.64%
Unlock
2027
49.21% 3.60%
Unlock
2028
52.20% 6.08%
Unlock

3 ADMA Biologics, Inc. Analysts have issued a net profit forecast 2024. The average ADMA Biologics, Inc. net profit estimate is

$112m
Unlock
. This is
242.84% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$114m 249.99%
Unlock
, the lowest is
$107m 228.56%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-30.3m 60.61%
2024
$112m 469.22%
Unlock
2025
$151m 34.73%
Unlock
2026
$158m 4.64%
Unlock
2027
$184m 16.50%
Unlock
2028
$225m 22.42%
Unlock

Net Margin

2023 -11.73% 76.49%
2024
27.58% 335.09%
Unlock
2025
32.89% 19.25%
Unlock
2026
30.87% 6.14%
Unlock
2027
31.89% 3.30%
Unlock
2028
32.62% 2.29%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -0.13 0.48
60.61% 469.23%
P/E 40.35
EV/Sales 11.27

3 Analysts have issued a ADMA Biologics, Inc. forecast for earnings per share. The average ADMA Biologics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$0.48
Unlock
. This is
242.86% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$0.49 250.00%
Unlock
, the lowest is
$0.46 228.57%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-0.13 60.61%
2024
$0.48 469.23%
Unlock
2025
$0.65 35.42%
Unlock
2026
$0.68 4.62%
Unlock
2027
$0.79 16.18%
Unlock
2028
$0.97 22.78%
Unlock

P/E ratio

Current 137.77 913.28%
2024
40.35 70.71%
Unlock
2025
29.95 25.77%
Unlock
2026
28.63 4.41%
Unlock
2027
24.57 14.18%
Unlock
2028
20.07 18.32%
Unlock

Based on analysts' sales estimates for 2024, the ADMA Biologics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

11.27
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
11.13
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 13.83 245.75%
2024
11.27 18.55%
Unlock
2025
9.97 11.50%
Unlock
2026
8.94 10.30%
Unlock
2027
7.93 11.32%
Unlock
2028
6.63 16.45%
Unlock

P/S ratio

Current 13.67 282.19%
2024
11.13 18.56%
Unlock
2025
9.85 11.50%
Unlock
2026
8.84 10.30%
Unlock
2027
7.84 11.32%
Unlock
2028
6.55 16.45%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today